INVESTOR PRESENTATION ex99-1.htm

Monday, March 16, 2015 BiopharmaWatch Research 1 min read

Key Takeaway: INVESTOR PRESENTATION ex99-1.htm

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Cash runway

~6 mo

Medium dilution risk

Lead asset

AV-101

Phase 1 · Healthy

INVESTOR PRESENTATION ex99-1.htm.